CompletedPhase 1

A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis

United States31 participantsStarted 2018-12-13

Plain-language summary

The purpose of this study is to evaluate the safety and tolerability of escalating, multiple subcutaneous (SC) doses of VIB7734 in participants with Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Systemic Lupus Erythematosus
✓. Cutaneous lupus erythematosus, including acute CLE, subacute CLE, and discoid lupus erythematosus
✓. Sjogren's syndrome (for Cohort 1 only)
✓. Systemic sclerosis (for Cohort 1 only)
✓. Probable or definite polymyositis (for Cohort 1 only)
✓. Probable or definite dermatomyositis (for Cohort 1 only)

What they're measuring

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)